Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Retin Cases Brief Rep ; 17(2): 170-172, 2023 Mar 01.
Article in English | MEDLINE | ID: mdl-33731604

ABSTRACT

PURPOSE: To describe a novel office procedure that permits the repositioning of an Ozurdex implant from the anterior chamber back into the vitreous cavity. METHODS: Description of an office technique for Ozurdex repositioning using a 30-gauge needle. RESULTS: In both cases, the Ozurdex implant was successfully returned to the vitreous cavity. In Case 1, the patient's visual acuities 1 and 2 weeks after this were 20/70 and 20/40, respectively, and had no further complications. In Case 2, the patient returned 1 week later, with the implant remaining posterior and a visual acuity of 20/40. CONCLUSION: The success of this novel technique in these cases demonstrates the potential to avoid a surgical procedure in the event of Ozurdex implant migration to the anterior chamber, while at the same time allowing the Ozurdex implant to remain effective in the eye.


Subject(s)
Foreign-Body Migration , Macular Edema , Humans , Foreign-Body Migration/surgery , Macular Edema/complications , Dexamethasone , Glucocorticoids , Anterior Chamber/surgery , Office Management , Drug Implants
2.
World Neurosurg ; 143: 134-146, 2020 11.
Article in English | MEDLINE | ID: mdl-32717353

ABSTRACT

In neurosurgery, parenchymal injury resulting from focal exertion of pressure on retracted tissue is a common complication associated with the use of plate and self-sustaining retractors to access deep intraparenchymal lesions. Tubular retractors, including Vycor, BrainPath, and METRx, were developed to reduce retraction injuries via radial dispersion of force. Our study seeks to compare these retraction systems and assess their respective indications, benefits, and associated complications. A systematic review of PubMed MEDLINE, Cochrane Central Register of Controlled Trials, Web of Science, and Cochrane Database of Systematic Reviews was performed. Twenty-nine articles (n = 289 patients) for BrainPath, 12 articles (n = 106 patients) for Vycor, and 3 articles for METRx (n = 31 patients) met the inclusion criteria. This report is the first formal comparison of the BrainPath, Vycor, and METRx tubular retraction systems. We found that all 3 retractors were effective in accessing intraparenchymal lesions. Although we found that the retractor systems were used more commonly in different locations and for different diseases, there was no significant difference in complications or mortality among the 3 retractors.


Subject(s)
Brain Diseases/surgery , Brain/surgery , Neurosurgical Procedures/instrumentation , Surgical Instruments , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...